Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
1.
Vaccine ; 40(35): 5263-5274, 2022 08 19.
Artigo em Inglês | MEDLINE | ID: mdl-35715351

RESUMO

Inactivated viral vaccines have long been used in humans for diseases of global health threat (e.g., poliomyelitis and pandemic and seasonal influenza) and the technology of inactivation has more recently been used for emerging diseases such as West Nile, Chikungunya, Ross River, SARS and especially for COVID-19. The Brighton Collaboration Benefit-Risk Assessment of VAccines by TechnolOgy (BRAVATO) Working Group has prepared standardized templates to describe the key considerations for the benefit and risk of several vaccine platform technologies, including inactivated viral vaccines. This paper uses the BRAVATO inactivated virus vaccine template to review the features of an inactivated whole chikungunya virus (CHIKV) vaccine that has been evaluated in several preclinical studies and clinical trials. The inactivated whole CHIKV vaccine was cultured on Vero cells and inactivated by ß-propiolactone. This provides an effective, flexible system for high-yield manufacturing. The inactivated whole CHIKV vaccine has favorable thermostability profiles, compatible with vaccine supply chains. Safety data are compiled in the current inactivated whole CHIKV vaccine safety database with unblinded data from the ongoing studies: 850 participants from phase II study (parts A and B) outside of India, and 600 participants from ongoing phase II study in India, and completed phase I clinical studies for 60 subjects. Overall, the inactivated whole CHIKV vaccine has been well tolerated, with no significant safety issues identified. Evaluation of the inactivated whole CHIKV vaccine is continuing, with 1410 participants vaccinated as of 20 April 2022. Extensive evaluation of immunogenicity in humans shows strong, durable humoral immune responses.


Assuntos
COVID-19 , Febre de Chikungunya , Vírus Chikungunya , Vacinas Virais , Animais , Anticorpos Antivirais , COVID-19/prevenção & controle , Febre de Chikungunya/prevenção & controle , Chlorocebus aethiops , Humanos , Medição de Risco , Vacinas de Produtos Inativados , Células Vero
2.
Sci Rep ; 7: 46375, 2017 04 12.
Artigo em Inglês | MEDLINE | ID: mdl-28401907

RESUMO

Zika virus (ZIKV) is a mosquito-borne flavivirus that causes asymptomatic infection or presents only mild symptoms in majority of those infected. However, vaccination for ZIKV is a public health priority due to serious congenital and neuropathological abnormalities observed as a sequelae of the virus infection in the recent epidemics. We have developed an inactivated virus vaccine with the African MR 766 strain. Here we show that two doses of the vaccine provided 100% efficacy against mortality and disease following challenge with homotypic MR 766 and the heterotypic FSS 13025 ZIKV strains in the Type I and Type II interferon deficient AG129 mice. Two doses of the vaccine elicited high titer of neutralizing antibodies in Balb/c mice, and the vaccine antisera conferred protection against virus challenge in passively immunized mice. The studies were useful to rationalize vaccine doses for protective efficacy. Furthermore, the vaccine antisera neutralized the homotypic and heterotypic ZIKV strains in vitro with equivalent efficiency. Our study suggests a single ZIKV serotype, and that the development of an effective vaccine may not be limited by the choice of virus strain.


Assuntos
Vacinas Virais/uso terapêutico , Infecção por Zika virus/prevenção & controle , Zika virus/imunologia , Animais , Anticorpos Neutralizantes/imunologia , Anticorpos Antivirais/imunologia , Modelos Animais de Doenças , Camundongos , Resultado do Tratamento , Proteínas do Envelope Viral/imunologia
3.
Antimicrob Agents Chemother ; 58(3): 1630-8, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-24366730

RESUMO

Staphylococci are the leading cause of hospital-acquired infections worldwide. Increasingly, they resist antibiotic treatment owing to the development of multiple antibiotic resistance mechanisms in most strains. Therefore, the activity and efficacy of recombinant lysostaphin as a drug against this pathogen have been evaluated. Lysostaphin exerts high levels of activity against antibiotic-resistant strains of Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA). The therapeutic value of lysostaphin has been analyzed in two different clinically relevant in vivo models, a catheter-associated infection model and a thigh infection model. We infected mice with luciferase-expressing S. aureus Xen 29, and the efficacies of lysostaphin, vancomycin, oxacillin, and combined lysostaphin-oxacillin were investigated by determining numbers of CFU, detecting bioluminescent signals, and measuring the accumulation of perfluorocarbon emulsion at the site of infection by (19)F magnetic resonance imaging. Lysostaphin treatment significantly reduced the bacterial burden in infected thigh muscles and, after systemic spreading from the catheter, in inner organs. The efficiency of lysostaphin treatment was even more pronounced in combinatorial therapy with oxacillin. These results suggest that recombinant lysostaphin may have potential as an anti-S. aureus drug worthy of further clinical development. In addition, both imaging technologies demonstrated efficacy patterns similar to that of CFU determination, although they proved to be less sensitive. Nonetheless, they served as powerful tools to provide additional information about the course and gravity of infection in a noninvasive manner, possibly allowing a reduction in the number of animals needed for research evaluation of new antibiotics in future studies.


Assuntos
Antibacterianos/uso terapêutico , Infecções Relacionadas a Cateter/tratamento farmacológico , Lisostafina/uso terapêutico , Oxacilina/uso terapêutico , Infecções Estafilocócicas/tratamento farmacológico , Animais , Antibacterianos/administração & dosagem , Modelos Animais de Doenças , Quimioterapia Combinada , Feminino , Radioisótopos de Flúor , Medições Luminescentes/métodos , Lisostafina/administração & dosagem , Imageamento por Ressonância Magnética , Staphylococcus aureus Resistente à Meticilina/efeitos dos fármacos , Camundongos , Camundongos Endogâmicos BALB C , Testes de Sensibilidade Microbiana , Oxacilina/administração & dosagem , Coxa da Perna/microbiologia
4.
Acta Virol ; 57(4): 471-3, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-24294963

RESUMO

Chikungunya virus (CHIKV), an Alphavirus of the family Togaviridae is a positive strand RNA virus that is transmitted commonly by the Aedes mosquitoes. The characteristic clinical symptom of the virus infection is incapacitating arthralgia that could persist for few weeks to several months in the affected individuals (1, 2). High morbidity with severe polyarthralgia, rashes and ocular, hemorrhagic and sensorineural complications are reported in the re-emerging infection (3-5). The acquisition of an A226V mutation in the envelope protein E1 has increased the transmissibility of the virus in the widely prevalent Ae. Albopictus mosquitoes (6). CHIKV infection has become more widespread in the recent years as the mosquito vectors have expanded into new areas. Imported cases of CHIKV have been reported in nearly 40 countries until now (7).


Assuntos
Infecções por Alphavirus/imunologia , Anticorpos Antivirais/imunologia , Vírus Chikungunya/imunologia , Infecções por Alphavirus/diagnóstico , Infecções por Alphavirus/prevenção & controle , Infecções por Alphavirus/virologia , Anticorpos Antivirais/sangue , Febre de Chikungunya , Vírus Chikungunya/genética , Humanos , Imunidade
5.
J Med Virol ; 84(3): 462-70, 2012 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-22246833

RESUMO

The genetic diversity of Chikungunya virus (CHIKV) causing recurring outbreaks in India since 2006 was studied. The 2006 epidemic was caused by a virus strain of the East, Central and South African (ECSA) genotype with 226A in the E1 glycoprotein. The variant strain with E1-A226V mutation caused outbreaks since 2007 in the state of Kerala where Aedes albopictus is the abundant mosquito vector. Molecular epidemiology data since 2007 is scarce from other regions of the country. RT-PCR, sequencing and phylogenetic analyses of CHIKV isolates from the 2009 to 2010 epidemics in the States of Tamil Nadu and Andhra Pradesh placed them in a separate clade within the ECSA lineage. The isolates of the study had 226A in the E1 glycoprotein. The isolates had a novel E1-K211E mutation that was under significant positive selection. E1-211E is highly conserved in the Asian genotype of the virus circulated by Aedes aegypti. Unique mutations in E2 glycoprotein were identified. The two sub-lineages of ECSA genotype circulating in India parallel the abundance of Ae. albopictus and Ae. aegypti. Novel mutations in the envelope glycoproteins suggest adaptive evolution of the virus to local vector abundance. Cross neutralization of the virus isolates from recurring Indian epidemics indicated that no distinct serotypes had evolved. The study has provided insights into the origin, distribution and evolutionary adaptation of the virus to local vector abundance in the region that has reportedly, the highest incidence of CHIKV infection in the world.


Assuntos
Infecções por Alphavirus/epidemiologia , Vírus Chikungunya/classificação , Vírus Chikungunya/genética , Surtos de Doenças , Evolução Molecular , Variação Genética , Infecções por Alphavirus/virologia , Índia/epidemiologia , Mutação , Filogenia , Seleção Genética , Sorotipagem/métodos , Proteínas do Envelope Viral/genética
6.
Arch Biochem Biophys ; 427(1): 116-22, 2004 Jul 01.
Artigo em Inglês | MEDLINE | ID: mdl-15178494

RESUMO

Human hypoxanthine guanine phosphoribosyltransferase (HGPRT) lacks the ability to phosphoribosylate xanthine, a property exhibited by HGPRTs from many parasitic protozoa. Using random mutagenesis we have obtained a mutant, F36L, of human HGPRT that phosphoribosylates xanthine. Examination of the structure indicates that F36 does not make direct contact with the purine, but long-range modulation via loop IV, a segment contacting purine at C2 position, could influence substrate specificity. Expanded substrate specificity to include xanthine probably arises from increased flexibility of loop IV as a consequence of mutation at F36. Mutation of the corresponding residue, L44 in Plasmodium falciparum HGPRT, also results in alteration of K(m) and k(cat) for xanthine, substantiating its role in affecting purine base affinity. Our studies show that mutation of this residue in the core of the protein also affects the stability of both enzymes.


Assuntos
Hipoxantina Fosforribosiltransferase/metabolismo , Animais , Sequência de Bases , Sítios de Ligação , Primers do DNA , Humanos , Hipoxantina Fosforribosiltransferase/química , Hipoxantina Fosforribosiltransferase/genética , Cinética , Modelos Moleculares , Mutagênese Sítio-Dirigida , Plasmodium falciparum/enzimologia , Conformação Proteica , Especificidade por Substrato
7.
J Mol Biol ; 335(5): 1251-64, 2004 Jan 30.
Artigo em Inglês | MEDLINE | ID: mdl-14729341

RESUMO

In the absence of the de novo purine nucleotide biosynthetic pathway in parasitic protozoa, purine salvage is of primary importance for parasite survival. Enzymes of the salvage pathway are, therefore, good targets for anti-parasitic drugs. Adenylosuccinate synthetase (AdSS), catalysing the first committed step in the synthesis of AMP from IMP, is a potential target for anti-protozoal chemotherapy. We report here the crystal structure of adenylosuccinate synthetase from the malaria parasite, Plasmodium falciparum, complexed to 6-phosphoryl IMP, GDP, Mg2+ and the aspartate analogue, hadacidin at 2 A resolution. The overall architecture of P. falciparum AdSS (PfAdSS) is similar to the known structures from Escherichia coli, mouse and plants. Differences in substrate interactions seen in this structure provide a plausible explanation for the kinetic differences between PfAdSS and the enzyme from other species. Additional hydrogen bonding interactions of the protein with GDP may account for the ordered binding of substrates to the enzyme. The dimer interface of PfAdSS is also different, with a pronounced excess of positively charged residues. Differences highlighted here provide a basis for the design of species-specific inhibitors of the enzyme.


Assuntos
Adenilossuccinato Sintase/química , Glicina/análogos & derivados , Plasmodium falciparum/enzimologia , Proteínas Recombinantes/química , Adenilossuccinato Sintase/metabolismo , Sequência de Aminoácidos , Animais , Sítios de Ligação , Cristalografia por Raios X , Dimerização , Glicina/metabolismo , Guanosina Difosfato/metabolismo , Ligação de Hidrogênio , Inosina Monofosfato/metabolismo , Magnésio/metabolismo , Modelos Moleculares , Dados de Sequência Molecular , Estrutura Molecular , Conformação Proteica , Proteínas Recombinantes/isolamento & purificação , Homologia de Sequência de Aminoácidos
8.
Protein Expr Purif ; 25(1): 65-72, 2002 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-12071700

RESUMO

Most parasitic protozoa lack the de novo purine biosynthetic pathway and rely exclusively on the salvage pathway for their purine nucleotide requirements. Enzymes of the salvage pathway are, therefore, candidate drug targets. We have cloned the Plasmodium falciparum adenylosuccinate synthetase gene. In the parasite, adenylosuccinate synthetase is involved in the synthesis of AMP from IMP formed during the salvage of the purine base, hypoxanthine. The gene was shown to code for a functionally active protein by functional complementation in a purA mutant strain of Escherichia coli, H1238. This paper reports the conditions for hyperexpression of the recombinant protein in E. coli BL21(DE3) and purification of the protein to homogeneity. The enzyme was found to require the presence of dithiothreitol during the entire course of the purification for activity. Glycerol and EDTA were found to stabilize enzyme activity during storage. The specific activity of the purified protein was 1143.6 +/- 36.8 mUnits/mg. The K(M)s for the three substrates, GTP, IMP, and aspartate, were found to be 4.8 microM, 22.8 microM, and 1.4 mM, respectively. The enzyme was a dimer on gel filtration in buffers of low ionic strength but equilibrated between a monomer and a dimer in buffers of increased ionic strength.


Assuntos
Adenilossuccinato Sintase/biossíntese , Adenilossuccinato Sintase/química , Escherichia coli/metabolismo , Plasmodium falciparum/enzimologia , Proteínas Recombinantes/química , Proteínas Recombinantes/isolamento & purificação , Animais , Ácido Aspártico/farmacologia , Western Blotting , Cromatografia em Gel , Clonagem Molecular , DNA Complementar/metabolismo , Dimerização , Ácido Edético/farmacologia , Teste de Complementação Genética , Glicerol/farmacologia , Guanosina Trifosfato/metabolismo , Inosina Monofosfato/farmacologia , Cinética , Modelos Químicos
9.
Gene ; 191(1): 103-7, 1997 May 20.
Artigo em Inglês | MEDLINE | ID: mdl-9210595

RESUMO

Transforming Growth Factors-beta (TGF-betas) have been described in many vertebrate species of amphibians, aves and mammals. In this report we demonstrate the presence of TGF-beta2 in pisces. TGF-beta2 has been cloned from a fish, Cyprinus carpio, by RT-PCR using degenerate oligonucleotide primers. Sequence analysis of the amplified product and alignment of the deduced amino acid sequence with the human TGF-beta2 amino acid sequence revealed 81% and 93% identity in the precursor and the mature regions, respectively. The northern blot analysis of fish heart RNA shows a major messenger RNA species of about 8.0 kb and two messages of very low abundance of about 5.0 kb and 4.0 kb. The identification of TGF-beta2 isoform in Pisces and it's high degree of homology with the mammalian isoform suggests that among all TGF-beta isoforms, TGF-beta2 is the most conserved during evolution.


Assuntos
Carpas/genética , Reação em Cadeia da Polimerase , Fator de Crescimento Transformador beta/genética , Sequência de Aminoácidos , Animais , Sequência de Bases , Northern Blotting , DNA Complementar/isolamento & purificação , Humanos , Dados de Sequência Molecular , Análise de Sequência de DNA , Homologia de Sequência de Aminoácidos , Fator de Crescimento Transformador beta/isolamento & purificação
10.
Indian J Biochem Biophys ; 33(6): 512-8, 1996 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-9219438

RESUMO

Glucose-6-phosphate dehydrogenase from rat brain was purified 13,000 fold to a specific activity of 480 units/mg protein. The molecular weight was 121 kDa. The kinetics of brain glucose-6-phosphate dehydrogenase are compatible with a model involving two possible states of the enzyme with a low and high affinity for the substrate D-glucose-6-phosphate. NADP+ and ADP offered protection against p-chloromercuribenzoate inhibition. NADPH is a powerful competitive inhibitor with respect to NADP+. The apparent Ki for NADPH inhibition was lower than the Km for NADP+. ADP inhibited the enzyme competitively with respect to NADP+. ATP inhibited the enzyme non-competitively with respect to NADP+, whereas kinetics of mixed inhibition was observed with respect to substrate D-glucose-6-phosphate. The interplay between NADP+ and NADPH leading to enzyme activation or inhibition according to their relative or absolute concentrations as well as the control of enzyme activity by the adenine nucleotide system may contribute a refined mechanism for the regulation of glucose-6-phosphate dehydrogenase and therefore the pentose phosphate pathway in brain.


Assuntos
Encéfalo/enzimologia , Glucosefosfato Desidrogenase/metabolismo , Difosfato de Adenosina/farmacologia , Trifosfato de Adenosina/farmacologia , Animais , Inibidores Enzimáticos/farmacologia , Glucosefosfato Desidrogenase/antagonistas & inibidores , Glucosefosfato Desidrogenase/isolamento & purificação , Cinética , Masculino , NADP/farmacologia , Ratos , Ratos Wistar
11.
Biochem Int ; 24(6): 1111-8, 1991 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-1781790

RESUMO

In mammary gland slices from lactating rats, vanadate increased the rate of glucose oxidation via the pentose phosphate pathway by 36% and raised the glucose flux via glycolysis by 47%. Furthermore, vanadate increased the fructose 2,6-bisphosphate (Fru-2,6-P2) level by 33%. The effect of vanadate on glucose oxidation was compared to the effect of insulin. The present data indicate that 0.5mM vanadate has an effect on glucose utilization similar to that of insulin but does not reach the same level.


Assuntos
Frutosedifosfatos/metabolismo , Glicólise/efeitos dos fármacos , Glândulas Mamárias Animais/metabolismo , Via de Pentose Fosfato/efeitos dos fármacos , Vanadatos/farmacologia , Animais , Feminino , Glucose/metabolismo , Técnicas In Vitro , Insulina/farmacologia , Lactação , Lipídeos/biossíntese , Glândulas Mamárias Animais/efeitos dos fármacos , Ratos , Ratos Endogâmicos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA